OncoMatch/Prostate Cancer/BRCA2
Prostate CancerBRCA2 Clinical Trials
BRCA2 alterations are the most common actionable alteration in prostate cancer (~5–8% of mCRPC) and are strongly associated with aggressive disease, high Gleason grade, and exceptional PARP inhibitor sensitivity. Olaparib and niraparib plus abiraterone are FDA-approved for BRCA2-altered mCRPC. Active trials study PARP inhibitor maintenance in earlier disease settings, combinations with lutetium-177 PSMA therapy, and somatic BRCA2 alteration eligibility expansion.
Top recruiting BRCA2 Prostate Cancer trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
AstraZeneca
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Canadian Cancer Trials Group
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer Clinical Trials Consortium
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
University of Maryland, Baltimore
Browse other molecular targets with active Prostate Cancer trials.